ALXO

ALX ONCOLOGY HOLDINGS INC ALXO

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-17.97M

Quarter to Jun 30

Free cash flow

$-16.07M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$217.87M total
RA CAPITAL MANAGEMENT, L.P.
$26.93M0.0%
venBio Partners LLC
$26.67M0.0%
BlackRock, Inc.
$15.32M+1552.4%
Redmile Group, LLC
$15.30M-7.2%
Blackstone Inc.
$13.65M+13.2%
DRIEHAUS CAPITAL MANAGEMENT LLC
$12.47M+5.1%
SILVERARC CAPITAL MANAGEMENT, LLC
$11.89MNew
TCG Crossover Management, LLC
$11.71M-56.5%
VANGUARD CAPITAL MANAGEMENT LLC
$10.30M+19.0%
Vivo Capital, LLC
$6.59M0.0%
MARSHALL WACE, LLP
$6.36M-18.3%
5AM Venture Management, LLC
$6.33M0.0%
Almitas Capital LLC
$6.08M-7.4%
ORBIMED ADVISORS LLC
$5.93M0.0%
GEODE CAPITAL MANAGEMENT, LLC
$5.77M+465.0%
TWO SIGMA INVESTMENTS, LP
$4.51M+37.2%
MILLENNIUM MANAGEMENT LLC
$3.20M-22.4%
STATE STREET CORP
$3.10M+752.5%
ACADIAN ASSET MANAGEMENT LLC
$2.71M+19.3%
JPMORGAN CHASE & CO
$2.30MNew
NORTHERN TRUST CORP
$1.94M+583.1%
Ensign Peak Advisors, Inc
$1.68M-14.8%
Nantahala Capital Management, LLC
$1.55MNew
VANGUARD PORTFOLIO MANAGEMENT LLC
$1.55M+665.4%
VANGUARD FIDUCIARY TRUST CO
$1.54M+152.5%
See all 94 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Debt/Equity

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/ALXO

Earnings Per Share

13fpro.ai/company/ALXO

Loading ratio trend…

ALXO key financials by period

Reported revenue, net income and operating margin by fiscal year, from ALX ONCOLOGY HOLDINGS INC's annual filings on SEC EDGAR.

ALX ONCOLOGY HOLDINGS INC reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2020$1.2M$-45.7M—
FY 2019$4.8M$-19.2M—
FY 2018$2.1M$-13.7M—
Source: ALXO filings on SEC EDGAR →

ALXO insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About ALX ONCOLOGY HOLDINGS INC (ALXO): stock profile, AI score and financials

ALX ONCOLOGY HOLDINGS INC (ALXO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. ALXO is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), ALX ONCOLOGY HOLDINGS INC reports net income of $-18.0M, free cash flow of $-16.1M. Top institutional holders of ALXO by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., venBio Partners, BlackRock, based on the most recent SEC filings. ALXO trades on the Nasdaq exchange and files with the SEC under CIK 1810182. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ALXO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ALX ONCOLOGY HOLDINGS INC directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1810182 →